SCHEMBL4690336

SCHEMBL4690336

Cc1ccc(-c2ccoc2C(=O)NC2CCN(CCCc3ccccc3NC(=O)O)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
DRD4 P21917 3/20 0.41
TSHR P16473 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK10 P53779 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
MAPK1 P28482 1/20 0.40
KCNH2 Q12809 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39
ATM Q13315 1/20 0.39
MCHR1 Q99705 1/20 0.39
TMEM97 Q5BJF2 1/20 0.38
CHRM3 P20309 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107491 0.88 HTR4 (0.37) ADRA1DADRA1AADRA1BDRD4TSHR
SCHEMBL4690214 0.88 PDE10A (0.43) ADRA1DADRA1AADRA1BDRD4TSHR
SCHEMBL4690337 0.85 HTR7 (0.37) DRD4TSHRSMN1; SMN2MAPK10MCHR1
SCHEMBL4690106 0.83 PDE10A (0.44) ADRA1DADRA1AADRA1BDRD4TSHR
SCHEMBL4690619 0.78 CA12 (0.47) SMN1; SMN2NPSR1CARM1PRMT6KCNH2
SCHEMBL10847812 0.77 SIGMAR1 (0.59) DRD4CARM1PRMT6MCHR1TMEM97
SCHEMBL4687556 0.75 TSHR (0.43) TSHRSMN1; SMN2MAPK10MAPK1ALDH1A1
SCHEMBL4693190 0.74 L3MBTL1 (0.39) ADRA1DADRA1AADRA1BDRD4TSHR
SCHEMBL4687554 0.73 L3MBTL1 (0.38) TSHRSMN1; SMN2CARM1PRMT6MAPK1
SCHEMBL4691615 0.73 KCNH2 (0.42) ADRA1DADRA1AADRA1BSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1443046-B1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME KYORIN SEIYAKU KK (JP) 2008-12-17 EP disclosed
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. 2008-08-14 US disclosed
US-7375115-B2 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-05-20 US disclosed
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same KYORIN PHARMACEUTICAL CO., LTD. (JP) 2005-04-21 US disclosed
EP-1443046-A1 NOVEL 4-(2FUROYL)AMINOPIPERIDINES, INTERMEDIATES IN SYNTHESIZING THE SAME, PROCESS FOR PRODUCING THE SAME AND MEDICINAL USE OF THE SAME Kyorin Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194826-A1 Novel 4-(2-furoyl) aminopiperidienes, intermediates for synthesizing the same, processes for preparing the same and medicinal use of the same CYP4F2, CYP1A2, CYP4B1 ADRA1D 670/4885ADRA1A 507/4885ADRA1B 775/4885
US-20050085508-A1 Novel 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same OPRM1, OPRD1, HRH4 ADRA1D 96/4885ADRA1A 106/4885ADRA1B 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.